E-CEL UVEC Treatment for Anal Fissures

Part of paid clinical trials in New York, New York.

Sponsor: Weill Medical College of Cornell University
Study ID: NCT06456073
Phase: PHASE1
Status: Recruiting

Apply to this trial

Conditions

Chronic Anal Fissure

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Accepted

Interventions

E-CEL UVEC cells (AB-207) — BIOLOGICAL
Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)

Study Details

This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.

Key Dates

Start date: Sep 12, 2024
Status verified: Apr 2026
Primary completion: Dec 31, 2026
Completion: Dec 31, 2026

Study Design

Enrollment: 20 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Intervention Arm
Local percutaneous injection of E-CEL UVEC cells around the anal fissure

Primary Outcome Measure

Number of severe injection site reactions [ Time Frame: Up to 180 days ]

Central Contacts

Kelly Garrett, MD
646-962-2270
[email protected]
KM Muktasid
646-962-2789
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Weill Cornell Medicine	New York	New York	10065	KM Muktasid [email protected]

Find similar trials in New York, NY

By research site

Weill Cornell Medicine· New York, NY